DEF: Champions Oncology Sets Annual Meeting for Board, Auditor Votes

Champions Oncology, Inc. announces its Annual Meeting of Stockholders on October 16, 2025, to elect directors, ratify auditors, and approve executive compensation.

Summary

• The Annual Meeting of Stockholders is scheduled for Thursday, October 16, 2025, at 9:00 a.m. Eastern time, at the company's headquarters in Hackensack, New Jersey.
• Stockholders will vote on the election of seven Board of Director nominees for the ensuing year.
• The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026, will be put to a vote for ratification.
• A non-binding advisory resolution relating to the compensation of named executive officers will be presented for approval.
• The Record Date for determining stockholders entitled to notice and to vote at the meeting is August 22, 2025, with 13,788,421 shares of common stock outstanding.
• Proxy materials, including the 2025 Proxy Statement and 2025 Annual Report on Form 10-K, are available online, with physical copies provided upon request.
• The Board of Directors unanimously recommends voting FOR all proposed nominees for director, FOR the ratification of EisnerAmper LLP, and FOR the non-binding resolution approving executive compensation.

Sentiment

Score: 7

Explanation: The filing outlines routine corporate governance matters and upcoming stockholder votes. The significant improvement in net income for FY2025 is a positive financial indicator, although negative Total Share Return over multiple years and a minor Section 16(a) non-compliance for an executive are noted. Overall sentiment is neutral to slightly positive due to improved financial performance and robust governance structures.

Positives

• The Board of Directors maintains a majority of independent directors, with five out of seven directors classified as independent under Nasdaq Rules.
• The Audit Committee meets heightened independence standards and includes an 'audit committee financial expert,' Scott Tobin, enhancing financial oversight.
• The company has adopted a Code of Business Conduct and Ethics and an Insider Trading Policy to promote high ethical standards and compliance.
• An Executive Compensation Clawback Policy was adopted on December 1, 2023, aligning with SEC and Nasdaq rules for mandatory recovery of erroneously awarded incentive-based compensation.
• Net Income (Loss) significantly improved to $4,701,000 in fiscal year 2025, compared to a loss of $(7,276,000) in fiscal year 2024 and $(5,335,000) in fiscal year 2023.

Negatives

• Robert Brainin's Form 4 for options granted during fiscal 2025 was not filed in compliance with Section 16(a) of the Exchange Act.
• Brady Davis, who served as President, passed away unexpectedly in October 2024, resulting in the forfeiture of all his unvested equity awards.
• Total Share Return (TSR) has been negative for the past three fiscal years: $(135.94) in 2023, $(101.42) in 2024, and $(52.58) in 2025, indicating a decline in shareholder value.

Risks

• The Audit Committee oversees the company's cybersecurity risks, with periodic reports from senior leadership. While no material risks from known cybersecurity threats have been identified to date, the potential for such incidents remains a challenge.

Future Outlook

The Board of Directors will review the results of the non-binding advisory vote on executive compensation and consider them when making future decisions. The company's executive compensation program generally seeks to incentivize long-term performance, rather than aligning specifically with compensation paid for a particular year.

Management Comments

• The Board of Directors does not presently know of any other business that might be brought before the Meeting.
• The Compensation Committee believes that the total compensation for each of the named executive officers is reasonable and effectively achieves the designed objectives of driving superior business and financial performance, attracting, retaining and motivating our people, aligning our executives with stockholders long-term interests, focusing on the long-term and creating balanced program elements that encourage aligned, systemic, sustainable performance.

Industry Context

This proxy statement reflects standard corporate governance practices for a publicly traded company in the oncology sector. The focus on director elections, auditor ratification, and executive compensation is typical for an annual meeting. The adoption of a clawback policy aligns with recent regulatory mandates (Dodd-Frank Act and SEC rules), demonstrating compliance with evolving industry governance standards.

Comparison to Industry Standards

• The implementation of an Executive Compensation Clawback Policy aligns with recent SEC rules (Rule 10D-1 under the Exchange Act) and Nasdaq Listing Rule 5608, demonstrating compliance with evolving corporate governance standards.
• The Board's structure with a majority of independent directors (5 out of 7) is a common best practice for corporate governance, often exceeding minimum requirements for smaller public companies.
• The designation of an audit committee financial expert (Scott Tobin) is a standard requirement for public companies under SEC regulations, ensuring specialized oversight of financial reporting.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. David Sidransky, a director and beneficial owner of approximately 6.0% of common stock, received $12,000 in consulting fees during the fiscal year ended April 30, 2025, and $36,000 during the fiscal year ended April 30, 2024.

Stakeholder Impact

• Shareholders will directly influence corporate governance through their votes on director elections, auditor ratification, and executive compensation, shaping the company's future direction.
• Management will experience changes in leadership roles, with Robert Brainin becoming CEO and Ronnie Morris transitioning to Chairman, potentially impacting strategic and operational focus.
• Employees may be indirectly affected by executive compensation policies and overall company performance, which can influence morale and future compensation structures.
• Auditors (EisnerAmper LLP) will have their appointment ratified, confirming their continued role in ensuring the integrity of the company's financial statements.

Next Steps

• Stockholders are encouraged to vote on director nominees, auditor ratification, and executive compensation prior to or at the Annual Meeting on October 16, 2025.
• The Board of Directors will review the results of the non-binding advisory vote on executive compensation and consider them for future decisions.
• Preliminary voting results will be announced at the Annual Meeting, with final results published in a Current Report on Form 8-K within four business days.
• Stockholders wishing to present a proposal for the 2026 Annual Meeting must submit it in writing between April 1, 2026, and May 1, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, primarily detailing corporate governance, director elections, and executive compensation proposals. While the company reported a positive net income for FY2025 after two years of losses, the Total Share Return has been negative over the past three fiscal years, indicating a lack of significant stock price appreciation. The management changes and robust governance policies are standard for a public company. There are no immediate catalysts or significant red flags that would warrant a strong buy or sell recommendation based solely on the content of this filing. A 'hold' position is appropriate as investors await further operational and financial updates that could provide more definitive insights into the company's future performance.

Keywords

Champions Oncology, SEC filing, DEF 14A, proxy statement, annual meeting, corporate governance, board of directors, executive compensation, auditor ratification, stock options, equity incentive plan, financial reporting, risk management, cybersecurity, related party transactions